1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Zydus Lifesciences Limited

Zydus Lifesciences Limited

1,127.85
INR
-7.15
(-0.63%)
48.47EPS
23.69P/E
1.11TMarket Cap
Nov 04Next Earn
Zydus Lifesciences Limited
BSE:ZYDUSLIFE
(Bombay Stock Exchange)

Recent

price

1,127.85

P/E

ratio

23.69

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
43.61
49.72
60.12
68.96
83
92.08
89.55
113.13
124.53
134.92
137.97
144.84
166.18
187.97
224.34
265.54
283.21
Revenue per Share
6.95
6.37
6.38
7.85
11.22
18.89
14.53
17.35
18.06
11.49
20.84
43.83
19.3
38.14
44.97
50.09
46.94
Basic EPS, GAAP
1.28
-7.25
-1.18
4.09
4.7
9.09
-15.9
-1.27
2.19
19.8
23.83
8.81
16.32
22.63
50.56
-5.51
- -
Free Cash Flow per Basic Share
0.99
1.24
1.49
1.5
1.8
5.59
3.2
- -
3.5
6.98
0.01
3.64
2.63
6.14
3.01
10.99
- -
Dividend per Share
21.21
25.26
28.76
33.59
44.16
55.67
67.99
85.42
101.45
101.35
126.91
166.05
173.05
197.07
238.05
269.43
- -
Book Value per Share
15.25
14.49
18.94
24.15
35.03
44.52
43.91
59.4
32.51
35.14
62.61
102.64
114.81
118.78
153.91
96.43
- -
Tangible Book Value per Share
1,024
1,024
1,024
1,024
1,024
1,024
1,024
1,024
1,024
1,024
1,024
1,024
1,016
1,012
1,006
1,006
1,006
Basic Weighted Avg Shares
44,647
50,900
61,552
70,600
84,971
94,268
91,673
115,813
127,484
138,121
141,250
148,276
168,778
190,215
225,738
267,197
284,838
Sales/Revenue/Turnover
20.44
18.62
15.41
14.25
17.46
21.66
16.65
19.85
18.25
14.84
19.37
16.69
16.9
23.86
26.49
21.66
20.38
Operating Margin (%)
1,269
1,579
1,847
2,012
2,873
2,921
3,750
5,405
5,986
6,965
7,248
7,361
7,227
7,641
9,158
14,080
16,608
Depreciation Expense
7,110
6,526
6,535
8,036
11,485
19,339
14,877
17,758
18,488
11,766
21,336
44,873
19,603
38,595
45,255
50,400
47,212
Net Income, GAAP
12.63
14.23
14.69
11.25
17.95
8.45
7.98
24.21
22.26
21.39
8.07
18.03
22.7
20.33
23.43
24.09
23.96
Effective Tax Rate (%)
15.92
12.82
10.62
11.38
13.52
20.51
16.23
15.33
14.5
8.52
15.11
30.26
11.61
20.29
20.05
18.86
16.58
Profit Margin (%)
7,094
6,214
5,213
6,239
10,966
8,194
7,738
21,467
11,556
4,460
8,547
44,220
44,857
61,595
80,045
41,942
- -
Working Capital
7,629
13,223
14,260
13,622
11,504
8,964
24,684
25,551
39,497
32,291
6,246
3,782
198
251
321
38,563
- -
LT Debt
22,384
26,763
30,638
35,833
46,975
58,350
71,161
89,355
116,792
117,104
149,296
190,538
196,883
221,016
263,584
295,822
- -
Total Equity
26.48
17.87
12.73
12.3
16.44
23.8
13.56
13
10.56
6.68
11.78
9.85
7.88
16.04
16.14
10.77
- -
Return on Invested Capital (%)
24.45
17.37
13.09
14.17
16.98
24.86
14.67
13.65
11.48
7.14
11.34
20.79
8.72
17.27
16.96
14.61
- -
Return on Capital (%)
37.42
27.44
23.63
25.18
28.86
37.85
23.5
22.62
19.33
11.33
18.26
29.92
11.36
20.67
20.67
19.74
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
86,397
- -
LT Borrowings
- -
31,880
- -
LT Finance Leases
- -
6,683
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,006
1,006
998
Market Capitalization
920,352
876,631
1,109,976

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
199,061
- -
Cash, Cash Equivalents & STI
- -
49,711
- -
Accounts Receivable, Net
- -
54,157
- -
Inventories
- -
56,281
- -
Total Current Liabilities
- -
157,119
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
86,397
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.07%
14.94%
12.23%
Free Cash Flow
25.4%
14.03%
-110.91%
Net Income, GAAP
22.49%
35.9%
11.37%
Sales/Revenue/Turnover
11.28%
13.71%
18.37%
Total Cash Common Dividend
- -
5,006.4%
265.72%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
60,465
51,136
51,235
62,902
225,738
2026
64,670
- -
67,804
74,344
267,197
2027
78,020
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
14.11
9.06
10.17
11.64
44.97
2026
14.58
- -
10.36
12.65
50.09
2027
9.35
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
3.01
2026
- -
- -
- -
- -
10.99
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Zydus Lifesciences Limited (ZYDUSLIFE.NS) is an integrated global pharmaceutical company engaged in the discovery, development, manufacture, and marketing of a broad portfolio of branded and generic formulations, active pharmaceutical ingredients (APIs), vaccines, and consumer wellness products. The company offers therapeutic solutions across key segments including cardiovascular, diabetes, oncology, gastroenterology, dermatology, ophthalmology, nephrology, and pain management; its branded formulations feature flagship products such as Lipaglyn for dyslipidemia, Saroglitazar for diabetic dyslipidemia, and Oxipod for antibiotics; in the generics business, it supplies over 250 products to more than 50 countries via subsidiaries like Zydus Pharmaceuticals (USA) Inc. and Zydus Healthcare Ltd. (UK); additionally, it produces biosimilars, vaccines through its Cadila Pharmaceuticals division, and over-the-counter consumer brands under the Everyday range including nutritionals, dermatology, and personal care items. Headquartered in Ahmedabad, India, and founded in 1952 as part of the Cadila Group, Zydus Lifesciences operates manufacturing facilities across India, the United States, Brazil, and other regions, serving institutional, retail, and emerging markets with a focus on complex generics, novel drug delivery systems, and biologicals. In recent developments, the company expanded its U.S. presence through the 2024 FDA approval and launch of additional complex generics including Mycophenolate Mofetil tablets; formed strategic partnerships for biosimilar development in oncology and autoimmune therapies; completed acquisitions of select API assets to bolster vertical integration; and announced a INR 50 billion investment in new R&D and manufacturing capacities for high-potency APIs and biologics in 2025, alongside leadership enhancements in its U.S. generics division to drive ANDA filings targeting 25 approvals annually.